GlassScriptPhysician profile
David Allen Bulot
NPI 1225204837
$18,373.52
in general payments reported to CMS, 2019-2025
11 companies · $579 in 2025
The $579 reported for 2025 was more than what 80% of Oral and Maxillofacial Surgery providers received nationally (typical 2025 total: $150).
See the full distribution for Oral and Maxillofacial Surgery
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $273 · 2020: $277 · 2021: $8,397 · 2022: $606 · 2023: $2,454 · 2024: $5,788 · 2025: $579.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,337 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $2,470 · Honoraria: $1,000 · Travel and Lodging: $750 · Gift: $137 · Education: $100 · Entertainment: $26.42.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,336.95 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $2,470.44 |
| Honoraria | $1,000.00 |
| Travel and Lodging | $750.00 |
| Gift | $137.36 |
| Education | $100.00 |
| Entertainment | $26.42 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Straumann USA LLC | $15,791.60 | 2020-2025 | |
| Zimvie INC. | $876.95 | 2022-2025 | |
| Zimmer Biomet Holdings, INC. | $688.80 | 2019-2021 | |
| Biohorizons Implant Systems INC. | $281.26 | 2019-2025 | Biohorizons, Biohorizons Dental Implants |
| Depuy Synthes Sales INC. | $279.97 | 2021-2023 | Matrixorthognathic |
| Kls-Martin L.P. | $111.11 | 2023 | |
| Nobel Biocare USA | $103.82 | 2020-2022 | |
| Revance Therapeutics, INC. | $90.72 | 2024-2025 | Daxxify |
| Stryker Corporation | $61.14 | 2025 | Na |
| Kowa Pharmaceuticals America, INC. | $44.96 | 2022-2023 | Seglentis |
| Pacira Pharmaceuticals Incorporated | $43.19 | 2024-2025 | Exparel |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Bulot listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.